Supplementary data reveals GPX4 stability and CRC growth responses to RSL3, indicating a potential druggable target.
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
No takes yet. Share an insight, caveat, or question.
DeAngelo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: